Immunic (NASDAQ:IMUX) Price Target Cut to $10.00 by Analysts at D. Boral Capital

Immunic (NASDAQ:IMUX - Free Report) had its target price trimmed by D. Boral Capital from $17.00 to $10.00 in a research note released on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts have also recently weighed in on IMUX. B. Riley reaffirmed a "buy" rating and set a $5.00 price objective (down from $6.00) on shares of Immunic in a research report on Friday, May 23rd. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday, May 1st. Wall Street Zen downgraded Immunic from a "hold" rating to a "sell" rating in a report on Thursday, March 20th. Finally, William Blair restated an "outperform" rating on shares of Immunic in a research report on Friday, May 16th. One analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Immunic has an average rating of "Buy" and an average price target of $11.60.

Immunic Stock Performance

Shares of NASDAQ:IMUX traded down $0.02 on Thursday, hitting $0.66. The company's stock had a trading volume of 4,957,409 shares, compared to its average volume of 780,232. Immunic has a 12 month low of $0.56 and a 12 month high of $2.11. The company has a market capitalization of $63.15 million, a price-to-earnings ratio of -0.54 and a beta of 1.73. The stock's 50-day moving average is $1.00 and its two-hundred day moving average is $1.06.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.25). Equities analysts expect that Immunic will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

Institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. purchased a new stake in shares of Immunic in the fourth quarter worth $37,000. Barclays PLC purchased a new stake in shares of Immunic in the fourth quarter worth $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Immunic by 90.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock worth $205,000 after buying an additional 96,894 shares in the last quarter. Bridgeway Capital Management LLC raised its position in shares of Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock worth $215,000 after buying an additional 22,200 shares in the last quarter. Finally, Jane Street Group LLC raised its position in shares of Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after buying an additional 152,726 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.